This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
by Zacks Equity Research
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
by Moumi Mondal
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
by Moumi Mondal
HOLX is set to present new real-world data at RSNA 2025, showing how its AI-driven breast imaging tools boost workflow without sacrificing detection.
Should You Continue to Hold Hologic Stock Post Q4 Earnings?
by Moumi Mondal
HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.
Qiagen (QGEN) International Revenue in Focus: Trends and Expectations
by Zacks Equity Research
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Hologic Expands European Reach of Genius Digital Diagnostics System
by Moumi Mondal
HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of +5.17% and +1.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?